This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Oncology  • Genetic Disorders  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 122 words of the full text and any section headings.

In Reply: We thank Dr Niemann for pointing out the citation errors in our tables. The definitions of malignant disease for pheochromocytoma and paraganglioma remain controversial; given limited technology, they are operational definitions. Over the course of decades, experts have not come up with a consensus. For our study, we chose to use the most conservative operational definition, ie, only patients with distant metastases. The only absolute criterion for diagnosing a malignant pheochromocytoma is the presence of secondary tumor deposits in sites where chromaffin tissue is not normally found. This eliminates tumors of multicentric origin, which are usually benign and amenable to surgery.¹ We do not believe that our conclusions are affected by our review of the literature.

Financial Disclosures: None reported.

Hartmut P. H. Neumann, MD
Neumann@mm41.ukl.uni-freiburg.de
Medizinische Universitatsklinik
Freiburg, Germany

1. Neville AM. The adrenal medulla. In: Symington T, ed. Functional Pathology of the Human Adrenal Gland. London, England: Livingstone; 1969.

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2006;295:625.

RELATED ARTICLES

Predictors and Prevalence of Paraganglioma Syndrome Associated With Mutations of the SDHC Gene
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , and
JAMA. ;294():2057-2063.
FULL TEXT  

Paraganglioma Syndrome and Mutations of the SDHC Gene

JAMA. ;295():625-625.
FULL TEXT